SRPT Unveiled: The Shocking Truth Behind Sarepta Therapeutics Inc’s Latest Stock Movements
Needham has recently reiterated Sarepta Therapeutics Inc (SRPT) stock to Buy rating, as announced on November 27, 2024, according to Finviz. Earlier, on November 25, 2024, H.C. Wainwright had initiated the stock to Sell, setting a price target of $80. Cantor Fitzgerald also raised Overweight rating with a price target of $167. Additionally, Jefferies initiated […]
Sarepta Therapeutics Inc (SRPT) Surge: Analyzing Today’s Price Increase
H.C. Wainwright has recently initiated Sarepta Therapeutics Inc (SRPT) stock to Sell rating, as announced on November 25, 2024, according to Finviz. Earlier, on November 7, 2024, Cantor Fitzgerald had raised the stock from a Neutral to Overweight, setting a price target of $167 for SRPT stock. Jefferies also initiated Buy rating with a price […]
SRPT Stock Fluctuations: The Real Story
Jefferies has recently initiated Sarepta Therapeutics Inc (SRPT) stock to Buy rating, as announced on October 21, 2024, according to Finviz. Earlier, on October 10, 2024, Raymond James had resumed the stock to Outperform, setting a price target of $150. RBC Capital Mkts also raised Outperform rating with a price target of $182. Additionally, Citigroup […]
Sarepta Therapeutics Inc (SRPT) Stock: Beyond the Surface of Its Performance?
Raymond James has recently resumed Sarepta Therapeutics Inc (SRPT) stock to Outperform rating, as announced on October 10, 2024, according to Finviz. Earlier, on July 29, 2024, RBC Capital Mkts had raised the stock from a Sector Perform to Outperform, setting a price target of $182. Citigroup also reduced Neutral rating with a price target […]
What’s Behind the -1.33% Drop in Sarepta Therapeutics Inc (SRPT) Stock? Find Out Now!
Raymond James has recently resumed Sarepta Therapeutics Inc (SRPT) stock to Outperform rating, as announced on October 10, 2024, according to Finviz. Earlier, on July 29, 2024, RBC Capital Mkts had raised the stock from a Sector Perform to Outperform, setting a price target of $182. Citigroup also reduced Neutral rating with a price target […]
What’s Driving Sarepta Therapeutics Inc (SRPT) Stock’s -4.66% Plunge Over the Past Month?
Raymond James has recently resumed Sarepta Therapeutics Inc (SRPT) stock to Outperform rating, as announced on October 10, 2024, according to Finviz. Earlier, on July 29, 2024, RBC Capital Mkts had raised the stock from a Sector Perform to Outperform, setting a price target of $182. Citigroup also reduced Neutral rating with a price target […]
SRPT’s Latest Surge: What’s Behind the Spike?
RBC Capital Mkts has recently raised Sarepta Therapeutics Inc (SRPT) stock to Outperform rating, as announced on July 29, 2024, according to Finviz. Earlier, on June 26, 2024, Citigroup had reduced the stock from a Buy to Neutral, setting a price target of $176 for SRPT stock. Piper Sandler also initiated Overweight rating with a […]
Sarepta Therapeutics Inc (SRPT) Stock Price Reaches $120.4: What Factors Are Influencing This Level?
RBC Capital Mkts has recently raised Sarepta Therapeutics Inc (SRPT) stock to Outperform rating, as announced on July 29, 2024, according to Finviz. Earlier, on June 26, 2024, Citigroup had reduced the stock from a Buy to Neutral, setting a price target of $176 for SRPT stock. Piper Sandler also initiated Overweight rating with a […]
Why Is Sarepta Therapeutics Inc (SRPT) Stock Lagging Behind -8.77% from Its 50-Day SMA?
RBC Capital Mkts has recently raised Sarepta Therapeutics Inc (SRPT) stock to Outperform rating, as announced on July 29, 2024, according to Finviz. Earlier, on June 26, 2024, Citigroup had reduced the stock from a Buy to Neutral, setting a price target of $176 for SRPT stock. Piper Sandler also initiated Overweight rating with a […]
Why Did Sarepta Therapeutics Inc (SRPT) Stock See -21.18% Plunge in the Last 90 Days?
RBC Capital Mkts has recently raised Sarepta Therapeutics Inc (SRPT) stock to Outperform rating, as announced on July 29, 2024, according to Finviz. Earlier, on June 26, 2024, Citigroup had reduced the stock from a Buy to Neutral, setting a price target of $176 for SRPT stock. Piper Sandler also initiated Overweight rating with a […]
